Why caution is needed

• BP 100/60: Systolic of 100 mmHg sits right at the threshold flagged in the FDA carvedilol (Coreg) label - patients with a systolic BP under 100 mmHg are specifically called out as being at higher risk of hypotension-related renal function deterioration and are the group in whom caution is advised. A diastolic of 60 is also on the low side.
• PR 102: This is a mild sinus tachycardia, not bradycardia. The classic carvedilol "hold parameter" (reduce/withhold if HR < 55 bpm, per the Coreg prescribing information) doesn't apply here - so bradycardia itself isn't the issue.

What actually matters clinically

1. Why is the heart rate 102? If the tachycardia is compensatory - e.g., from hypovolemia, pain, fever, anxiety, early sepsis, or anemia - giving carvedilol could blunt that compensation while the alpha-blockade further drops BP, risking a hypotensive/hypoperfusion event. If it's a heart-failure or arrhythmia indication where carvedilol is genuinely needed, low-dose initiation may still be reasonable but with close monitoring.
2. Check indication and dose: A starting dose (e.g., 3.125-6.25 mg) in a patient with low-normal BP is generally what prescribers use ("caution should be exercised... a lower dosage of 3.125 mg twice daily... may be started" per Coreg dosing guidance), rather than skipping entirely, if the drug is truly indicated (e.g., heart failure, post-MI).
3. Standard nursing/clinical practice: many institutional protocols instruct holding beta-blockers (including carvedilol) if systolic BP is below ~90-100 mmHg, and this patient is right at that line - this is a "hold and notify physician" situation in most protocols rather than an automatic "give" or automatic "withhold."
4. Monitor for orthostatic hypotension: carvedilol dosing guidance recommends checking standing systolic BP about 1 hour after dosing, since postural hypotension is a recognized issue with this drug (Washington Manual of Medical Therapeutics).

Bottom line

• Not a hard contraindication at 100/60 with PR 102, but it is a borderline value that warrants clinical judgement, not routine administration.
• Best practice: verify the indication and prescribed dose, check for symptoms (dizziness, lightheadedness), consider postural vitals, and clarify with the prescribing physician/hold parameters set for that patient before administering - particularly if this is a first dose or dose increase.
• If institutional protocol specifies a hold parameter (commonly SBP < 90-100 mmHg and/or HR < 50-55 bpm), follow that and communicate the readings to the prescriber rather than giving or withholding unilaterally.

• This is on the low side. Carvedilol has both beta- and alpha-1 blocking activity, so it drops blood pressure further than a pure beta-blocker. The FDA label specifically notes that patients with systolic BP <100 mmHg are at higher risk of renal function deterioration and are more prone to symptomatic hypotension/syncope.
• At SBP of 100, giving carvedilol risks pushing the patient into symptomatic hypotension (dizziness, syncope, falls).

• Tachycardia at 102 with a low-normal/low BP is often the body's compensatory response (e.g., to hypovolemia, sepsis, anemia, pain, anxiety, or early shock). Heart rate itself is not a contraindication to a beta-blocker the way bradycardia is (the standard hold parameter is HR <55 bpm), but blunting the compensatory tachycardia with carvedilol in a patient who is already borderline hypotensive can be dangerous - it removes the heart's ability to compensate for a falling BP and can precipitate hypotensive collapse.

Does post-PTCA make this more or less safe?

• Access-site bleeding / retroperitoneal hematoma (femoral approach) - compensatory tachycardia with falling BP is the classic early sign, often before it becomes overtly obvious. Check the groin/wrist site, distal pulses, and abdomen/flank if femoral.
• Vasovagal reaction from sheath removal - usually causes bradycardia + hypotension, so less likely here given the tachycardia, but worth excluding if sheath was recently pulled.
• Volume depletion from contrast-induced diuresis or poor oral intake.
• Acute/subacute stent thrombosis or ischemia - can present as hypotension with reflex tachycardia before overt chest pain or ECG changes are obvious. A repeat ECG is worth doing if there's any doubt.

Practical recommendation

1. Confirm why the PTCA was done (elective for stable CAD vs. primary PCI for ACS) - this changes urgency but not the immediate caution.
2. Check the access site for bleeding/hematoma and assess volume status before assuming this is "baseline."
3. Get/repeat an ECG if there's any suspicion of ischemia.
4. If no bleeding, no ischemia, and the patient is otherwise clinically stable (just periprocedural pain/anxiety causing the tachycardia), a low starting dose of carvedilol as ordered, with close BP/HR monitoring, is reasonable.
5. If any suspicion of bleeding, hypovolemia, or ischemia - hold the dose and notify the treating physician immediately rather than giving it, since carvedilol would blunt the compensatory tachycardia and could worsen hypotension/hypoperfusion in an evolving complication.